Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05040659 · ClinicalTrials.gov registry record
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
A clinical trial of Healthy and Influenza, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT05040659 is a study of Healthy and Influenza that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 1,000 participants, above the 646-participant average among 1,090 other Healthy trials with a reported enrollment target (55% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05040659, a study of Healthy and Influenza, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn more about how to better track smell recovery in people who have been infected with the SARS-CoV-2 virus (which causes COVID-19). Many people who have been infected by this virus develop changes in their sense of smell (olfaction). We are interested in measuring smell function objectively via smell cards that test odor intensity, identification, and discrimination. Objective and precise olfactory testing that can be performed in the convenience of one's home will help identify people with smell loss after infection by SARS-CoV-2. We will use results from this test to better understand the relationship between SARS-CoV-2 infection and recovery of olfactory function and to learn whether the AROMHA longitudinal smell test is a reliable olfactory function tracking tool to quantify smell loss in the context of COVID infection. These results may inform the design of therapeutic clinical trials to accelerate the recovery of smell function.
Conditions Studied
Interventions
- DEVICE AROMHA Longitudinal Smell Test
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2022-11-14 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05040659
The ClinicalTrials.gov registry entry for NCT05040659 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 646-participant average among 1,090 other Healthy trials with a reported enrollment target (55% higher). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which AROMHA Longitudinal Smell Test is the first listed.
NCT05040659 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05040659 about?
NCT05040659 is a clinical study titled "Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2". The purpose of this study is to learn more about how to better track smell recovery in people who have been infected with the SARS-CoV-2 virus (which causes COVID-19). Many people who have been infected by this virus develop changes in their sense of smell (olfaction). We are interested in measuring...
What is the current status of trial NCT05040659?
This trial is currently active not recruiting. The enrollment target is 1,000 participants. The study started on 2022-11-14. Estimated completion is 2027-12-31.
What conditions does trial NCT05040659 study?
This clinical trial studies the following conditions: Healthy, Influenza, COVID-19 Respiratory Infection, PASC Post Acute Sequelae of COVID 19, Anosmia.
What interventions are being tested in trial NCT05040659?
The interventions under investigation include: AROMHA Longitudinal Smell Test (DEVICE).
Who is sponsoring clinical trial NCT05040659?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05040659 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
The Modulatory Effect of Female Sex Hormones on Spinal Neuroplasticity
RECRUITING
-
Breathing & Blood Pressure
RECRUITING
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.